Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
letter
. 2013 Apr 5;28(9):624–625. [Article in Spanish] doi: 10.1016/S0212-6567(01)70468-4

Algunas consideraciones sobre el Consenso de la Sociedad Española de Diabetes y de la Sociedad Española de Medicina de Familia y Comunitaria sobre los criterios y pautas de terapia combinada en la diabetes tipo 2

G Giménez-Péreza, JM González-Clemente a,b, A Caixàs a, D Mauricio a
PMCID: PMC7679639  PMID: 11747781

The content is available as a PDF (211.1 KB).

Bibliografía

  • 1.Criterios y pautas de terapia combinada en la diabetes tipo 2 Documento de consenso de la Sociedad Española de Diabetes y de la Sociedad Española de Medicina Familiar y Comunitaria. Endocrinologia. 2001;48:82–97. [Google Scholar]
  • 2.The Sixth Report of the Joint National Committee on Prevention, Detection Evaluation, Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413–2446. doi: 10.1001/archinte.157.21.2413. [DOI] [PubMed] [Google Scholar]
  • 3.Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
  • 4.Altman D.G., Schulz K.F., Moher D., Egger M., Davidoff F., Elbourne D. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663–694. doi: 10.7326/0003-4819-134-8-200104170-00012. [DOI] [PubMed] [Google Scholar]
  • 5.UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352:854–865. [PubMed] [Google Scholar]
  • 6.McCormark J., Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. BMJ. 2000;320:1720–1723. doi: 10.1136/bmj.320.7251.1720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.DeFronzo R.A., Barzilai N., Simonson D.C. Mechanism of metformin action in obese and lean non insulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991;73:1294–1301. doi: 10.1210/jcem-73-6-1294. [DOI] [PubMed] [Google Scholar]
  • 8.De Fronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Inter Med. 1999;131:281–303. doi: 10.7326/0003-4819-131-4-199908170-00008. [DOI] [PubMed] [Google Scholar]
  • 9.Olsson J., Lindberg G., Gottsater M., Lindwall K., Sjtistrand A., Tisell A. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia. 2000;43:558–560. doi: 10.1007/s001250051343. [DOI] [PubMed] [Google Scholar]
  • 10.Spallarossa P, Olivotti L, Schiavo M, Cordera R, Rossettin P, Brunelli C. Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia. Diabetes Care. 2001;24:738–742. doi: 10.2337/diacare.24.4.738. [DOI] [PubMed] [Google Scholar]
  • 11.Holman R.R, Cull C.A, Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44) Diabetes Care. 1999;22:960–964. doi: 10.2337/diacare.22.6.960. [DOI] [PubMed] [Google Scholar]
  • 12.American Diabetes Association Consensus Statement. Postprandial Blood Glucose. Diabetes Care. 2001;24:775–778. doi: 10.2337/diacare.24.4.775. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES